Scientists at University College London have developed a blood test capable of detecting Parkinson’s disease an average of 7.3 years before the first clinical symptoms emerge — a breakthrough that could fundamentally reshape how this neurodegenerative disease is managed, according to research published in Nature Medicine.
What the Test Measures
The test measures two biomarkers in blood plasma: phosphorylated alpha-synuclein (p-Syn) and a novel neurofilament light chain (NfL) ratio. In Parkinson’s disease, alpha-synuclein misfolds and aggregates into toxic clumps — Lewy bodies — that progressively destroy dopamine-producing neurons in the substantia nigra. The blood test detects the earliest biochemical evidence of this misfolding process, long before the motor symptoms of tremor, rigidity, and bradykinesia become apparent.
The Study
Researchers used the UK Biobank — a longitudinal cohort of 500,000 participants with blood samples collected from 2006 onwards — to identify 1,123 individuals who later received a confirmed Parkinson’s diagnosis. Comparing their stored blood samples against matched controls, the test demonstrated:
- Sensitivity: 87% — correctly identified 87% of future Parkinson’s cases
- Specificity: 91% — correctly ruled out 91% of controls
- Mean lead time: 7.3 years before symptom onset (range 3–14 years)
- Cost per test: Estimated £45 — compatible with population screening
“This changes everything. For the first time, we can identify people at risk before significant neurodegeneration has occurred — and that is precisely when any future neuroprotective therapy will be most effective.”
— Professor Huw Morris, UCL Queen Square Institute of Neurology, lead author
Why Early Detection Matters So Much
By the time a patient receives a clinical Parkinson’s diagnosis, approximately 60–80% of dopaminergic neurons in the substantia nigra have already been lost. Current treatments — levodopa, dopamine agonists, deep brain stimulation — manage symptoms but do not halt neurodegeneration. No approved disease-modifying therapy exists, in large part because every clinical trial has enrolled patients who are already too far into the disease course for neuroprotection to work.
A pre-symptomatic blood test creates the patient population needed to test preventive therapies. Multiple drug candidates targeting alpha-synuclein aggregation are currently in Phase 2 trials — including cinpanemab and prasinezumab — but have so far failed to show benefit in symptomatic patients. Researchers believe this is because treatment begins too late.
LRRK2 and GBA Variants
The test performed particularly well in individuals carrying known genetic risk variants. In carriers of the LRRK2 G2019S mutation — which accounts for approximately 1% of all Parkinson’s cases and up to 30% of Ashkenazi Jewish cases — sensitivity reached 94%. In GBA1 variant carriers, sensitivity was 89%. This suggests the test may first be deployed as a genetic risk stratification tool in high-risk families.
Path to Clinical Use
UCL has partnered with diagnostics company Roche to develop a standardised assay for clinical deployment. NHS England is evaluating a pilot screening programme targeting adults aged 55–65 with genetic risk factors or REM sleep behaviour disorder — a known Parkinson’s prodrome — with results expected in 2028.
In India, where Parkinson’s disease affects an estimated 800,000 people and is chronically underdiagnosed, the test’s low cost makes it potentially suitable for inclusion in tier-2 and tier-3 city neurology screening programmes.
What Patients Should Know Now
The test is not yet available outside clinical research settings. Neurologists caution against anxiety-driven private testing, noting that a positive result currently cannot be acted upon therapeutically. The appropriate response to a positive test in 2026 is enrollment in a clinical trial — not pharmacological treatment.
Leave a Reply